On March 25, 2022 Mission Therapeutics ("Mission"), a drug discovery and development company focused on protein homeostasis by selectively inhibiting deubiquitylating enzymes (DUBs), reported that members of its management team, Dr Anker Lundemose, CEO, David Luther, CFO, Dr Suhail Nurbhai, CMO, and Dr Paul Thompson, CSO, will be attending the upcoming SVB Leerink Biopharma Private Company Connect Event (Press release, Mission Therapeutics, MAR 25, 2022, View Source [SID1234610958]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event, which will take place virtually on 29-31 March, is intended to bring together private companies, institutional investors, and industry experts to discuss the trends and opportunities shaping the future of healthcare.

Companies and individuals interested in attending the conference should please contact SVB Leerink for more information.